Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research is ...
The allowed claims encompass GeoVax’s Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate, MVA-VLP-MUC1. The Company uses its MVA-VLP vaccine platform to express abnormal ...
智通财经APP获悉，今日(12月19日)，中国国家药监局药品审评中心(CDE)官网公示，第一三共(DSNKY.US)申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示，DS-3939a是一种靶向TA-MUC1的抗体偶联药物(ADC)， ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback